Cargando…

POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL

The importance of the cell surface receptor CXCR4 and the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) is well-established in normal and malignant hematopoiesis. The Protein Epitope Mimetic POL5551 is a novel and potent antagonist of CXCR4. POL5551 efficiently mobilizes hematopoietic stem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sison, Edward Allan R., Magoon, Daniel, Li, Li, Annesley, Colleen E., Romagnoli, Barbara, Douglas, Garry J., Tuffin, Gerald, Zimmermann, Johann, Brown, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741576/ https://www.ncbi.nlm.nih.gov/pubmed/26360610

Ejemplares similares

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
por: Sison, Edward Allan R., et al.
Publicado: (2014)

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
por: Karpova, Darja, et al.
Publicado: (2017)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
por: Song, Jen-Shin, et al.
Publicado: (2021)

Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity
por: Cohen, Gordon, et al.
Publicado: (2020)

Nucleoside Analogues Are Potent Inducers of Pol V-mediated Mutagenesis
por: Sumabe, Balagra Kasim, et al.
Publicado: (2021)

A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys
por: Fang, Xiao, et al.
Publicado: (2021)

A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection
por: Jenh, Chung-Her, et al.
Publicado: (2012)

Protective effect of a Protein Epitope Mimetic CCR10 antagonist, POL7085, in a model of allergic eosinophilic airway inflammation
por: Daubeuf, François, et al.
Publicado: (2015)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
por: Figueiredo, Anna, et al.
Publicado: (2006)

RNA Pol IV induces antagonistic parent-of-origin effects on Arabidopsis endosperm
por: Satyaki, Prasad R. V., et al.
Publicado: (2022)

Calcineurin/CXCR4 in T-ALL
por: Passaro, Diana, et al.
Publicado: (2015)

AllCoPol: inferring allele co-ancestry in polyploids
por: Lautenschlager, Ulrich, et al.
Publicado: (2020)

Genome-wide analyses of chromatin interactions after the loss of Pol I, Pol II, and Pol III
por: Jiang, Yongpeng, et al.
Publicado: (2020)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome
por: McDermott, David H, et al.
Publicado: (2011)

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

The stabilized Pol31–Pol3 interface counteracts Pol32 ablation with differential effects on repair
por: Shimada, Kenji, et al.
Publicado: (2021)

CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK–779
por: Nedjai, Belinda, et al.
Publicado: (2015)

A Potent Antagonist of Smoothened in Hedgehog Signaling for Epilepsy
por: Fan, Junwan, et al.
Publicado: (2022)

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
por: Annesley, Colleen E., et al.
Publicado: (2018)

Identification of a potent antagonist of smoothened in hedgehog signaling
por: Fan, Junwan, et al.
Publicado: (2021)

CXCR2 Antagonist RIST4721 Acts as a Potent Chemotaxis Inhibitor of Mature Neutrophils Derived from Ex Vivo-Cultured Mouse Bone Marrow
por: Szymczak, Klaudia, et al.
Publicado: (2023)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5
por: Fang, Xiaocui, et al.
Publicado: (2017)

Enhancer SINEs Link Pol III to Pol II Transcription in Neurons
por: Policarpi, Cristina, et al.
Publicado: (2017)

Chromatin remodeling by Pol II primes efficient Pol III transcription
por: Yague-Sanz, Carlo, et al.
Publicado: (2023)

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
por: Morimoto, Mamoru, et al.
Publicado: (2016)

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
por: Tamamura, Hirokazu, et al.
Publicado: (2008)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
por: Koenig, Lars M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k54qversctj211ev65lb4okudq